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AbstrAct
Objective
To estimate the risk of acute myocardial infarction 
(AMI) or stroke in adults with non-alcoholic fatty liver 
disease (NAFLD) or non-alcoholic steatohepatitis 
(NASH).
Design
Matched cohort study.
setting
Population based, electronic primary healthcare 
databases before 31 December 2015 from four 
European countries: Italy (n=1 542 672), Netherlands 
(n=2 225 925), Spain (n=5 488 397), and UK 
(n=12 695 046).
ParticiPants
120 795 adults with a recorded diagnosis of NAFLD 
or NASH and no other liver diseases, matched at time 
of NAFLD diagnosis (index date) by age, sex, practice 
site, and visit, recorded at six months before or after 
the date of diagnosis, with up to 100 patients without 
NAFLD or NASH in the same database.
Main OutcOMe Measures
Primary outcome was incident fatal or non-fatal AMI 
and ischaemic or unspecified stroke. Hazard ratios 
were estimated using Cox models and pooled across 
databases by random effect meta-analyses.
results
120 795 patients with recorded NAFLD or NASH 
diagnoses were identified with mean follow-up 2.1-
5.5 years. After adjustment for age and smoking the 
pooled hazard ratio for AMI was 1.17 (95% confidence 
interval 1.05 to 1.30; 1035 events in participants 
with NAFLD or NASH, 67 823 in matched controls). 
In a group with more complete data on risk factors 
(86 098 NAFLD and 4 664 988 matched controls), 
the hazard ratio for AMI after adjustment for systolic 
blood pressure, type 2 diabetes, total cholesterol 
level, statin use, and hypertension was 1.01 (0.91 to 
1.12; 747 events in participants with NAFLD or NASH, 
37 462 in matched controls). After adjustment for age 
and smoking status the pooled hazard ratio for stroke 
was 1.18 (1.11 to 1.24; 2187 events in participants 
with NAFLD or NASH, 134 001 in matched controls). In 
the group with more complete data on risk factors, the 
hazard ratio for stroke was 1.04 (0.99 to 1.09; 1666 
events in participants with NAFLD, 83 882 in matched 
controls) after further adjustment for type 2 diabetes, 
systolic blood pressure, total cholesterol level, statin 
use, and hypertension.
cOnclusiOns
The diagnosis of NAFLD in current routine care of 17.7 
million patient appears not to be associated with 
AMI or stroke risk after adjustment for established 
cardiovascular risk factors. Cardiovascular risk 
assessment in adults with a diagnosis of NAFLD is 
important but should be done in the same way as for 
the general population.
Introduction
For several years, researchers have proposed that, in 
addition to being a marker of ectopic fat accumulation 
and diabetes risk (which is unambiguous), non-
alcoholic fatty liver disease (NAFLD) might have 
important associations with cardiovascular outcomes.1 
The incidence of NAFLD has increased alongside that of 
obesity and diabetes worldwide, however its “impact” 
on complications from those conditions, including risk 
of cardiovascular disease, has not yet been established. 
In some ways this is not surprising because people 
with NAFLD often have abnormal glucose and lipid 
levels and are usually overweight or obese. Other 
mechanisms that could explain a possible association 
include increased oxidative stress, deranged adipokine 
profile, and hypercoagulability, which are more likely in 
people with NAFLD,2 giving rise to risk of AMI or stroke 
beyond those of traditional risk factors. Studies have 
shown an increased prevalence of surrogate markers 
in people with NAFLD: subclinical atherosclerosis,3-5 
subclinical AMI or stroke (Framingham study),3 and 
carotid atherosclerotic plaques.6 7 The severity of 
coronary artery disease was also higher in people with 
NAFLD referred for coronary angiography.8
Results from recent meta-analyses indicate that 
people with NAFLD are at risk of AMI or stroke. For 
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WhAt Is AlreAdy knoWn on thIs topIc
Non-alcoholic fatty liver disease (NAFLD) is associated with metabolic syndrome 
and other risk factors for acute myocardial infarction (AMI) or stroke
NAFLD is associated with increased risk of AMI and stroke and cardiovascular 
surrogate markers
The association between NAFLD and AMI and stroke after adjustment for 
established risk factors has yet to be fully established however
WhAt thIs study Adds
In four large European databases, the adjusted hazard ratios for incident AMI or 
stroke diagnoses in adults with NAFLD were modest and not significantly greater 
than those in age, sex, and general practice matched participants without NAFLD
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example, one meta-analysis reported an odds ratio 
of 2.05 (95% confidence interval 1.81 to 2.31) for 
incident cardiovascular disease events in people with 
ultrasound defined NAFLD compared with controls 
without NAFLD.9 Similarly, a recent meta-analysis of 
more than 34 000 participants reported an odds ratio 
of 1.64 (95% confidence interval 1.26 to 2.13) for 
combined fatal and non-fatal AMI or stroke events.10 
Heterogeneity in these two meta-analyses was moderate 
to high and the authors mentioned potential bias from 
variable and often incomplete adjustment for usual 
risk factors. Despite this limitation, the findings seem 
to suggest that people with NAFLD have risk levels for 
AMI or stroke approaching those for people with type 2 
diabetes. Such findings support the suggestion that all 
people with NAFLD should be treated for prevention of 
cardiovascular disease.1
The degree to which NAFLD contributes to the 
increased incidence of AMI or stroke is, however, 
debatable,11 particularly as most of the studies included 
in the two recent meta-analyses9 10 only partially 
adjusted for known risk factors, such as diabetes 
and lipid levels, which often coexist with NAFLD. 
In addition, few previous studies have considered 
geographical and other socioeconomic sources of 
heterogeneity. Furthermore, robust assessments of 
AMI or stroke risk in people with NAFLD compared 
with the general population are important to establish 
in routine healthcare in the real world, to help inform 
doctors about the management of cardiovascular 
risk in people with a diagnosis of NAFLD in routine 
clinical care. Such data would also help to determine 
whether an AMI or stroke risk multiplier should to be 
introduced for those with NAFLD, as has been done 
for people with diabetes or rheumatoid arthritis.12 We 
therefore undertook a longitudinal analysis of people 
with a recorded diagnosis of NAFLD in four European 
primary care databases, as part of the European 
Medical Information Framework (EMIF) to estimate the 
incident risk of developing acute myocardial infarction 
(AMI) and stroke in those cohorts identified in routine 
practice. When data were available, we sequentially 
adjusted for known cardiovascular risk factors, and in 
sensitivity analyses we investigated the associations in 
people with NAFLD without a subsequent diagnosis of 
NASH.
Methods
Databases
We included patient data from four primary care 
databases available through the EMIF network: The 
Health Improvement Network (THIN, UK), Health 
Search Database (HSD, Italy), Information System 
for Research in Primary Care (SIDIAP, Spain), 
and Integrated Primary Care Information (IPCI, 
Netherlands).13-17 The databases are compliant with 
local data protection laws. During data extraction, each 
data custodian liaised with the European Medicine 
Information Framework (EMIF)-Platform (www.emif.
eu). Data were then uploaded using a private remote 
secure server and analysed centrally.
study design
We adopted a matched cohort design. To ensure 
comparability between databases we generated code 
lists for clinical diagnoses (exclusion criteria, exposure, 
covariates, and events of interest) using a semantic 
harmonisation process that involved mapping concepts 
in each terminology (ICD-9 (international classification 
of diseases, ninth revision) codes for HSD, ICPC Dutch 
for IPCI, ICD-10 for SIDIAP, and Read codes for THIN) 
to unified medical language system concepts.18 In the 
four databases we identified people with a diagnosis 
of NAFLD (including non-alcoholic steatohepatitis 
(NASH)) before 1 January 2016. Owing to differences 
in coding terminology, recording of NASH diagnoses 
as distinct from NAFLD diagnoses was only possible 
in Spain (SIDIAP) and the UK (THIN). In the main 
analyses in these databases, people with NAFLD and 
NASH were grouped together, as was also the case in 
IPCI and HSD owing to the coding (ICPC Dutch codes 
and ICD-9 do not have distinctive codes for NAFLD and 
NASH). We carried out sensitivity analyses in SIDIAP 
and THIN excluding participants with NASH.
Each participant with NAFLD was matched with up 
to 100 participants without a diagnosis of NAFLD or 
NASH. Index date was the date of NAFLD diagnosis for 
each paired set. Matching was done on practice site (as 
a proxy for socioeconomic deprivation),19 age at index 
date within five years either way, sex, and a recorded 
date for visiting a general practitioner at index date 
within six months either way.
Participants with NAFLD and their matched 
controls were included in the analysis if they were 
aged 18 or more at diagnosis, remained active in the 
database for at least 12 months from registration 
and six months before the index date, and had at 
least six months of follow-up after the index date. We 
excluded participants with a record of alcohol misuse 
at any time before diagnosis or a past AMI or stroke 
event. Supplementary table 1 shows the flow chart of 
inclusion and exclusion criteria.
Participants were followed-up from index date 
until the earliest of occurrence of an event, end of 
study period (31 December 2015), or loss to follow-
up owing to exit from the database or death. Events of 
interest were fatal or non-fatal AMI and ischaemic or 
unspecified stroke.
variables
In Europe, primary care doctors store information on 
clinical diagnoses, prescriptions, lifestyle (smoking 
behaviours), vital signs, and procedures, and some-
times on socioeconomic information. When a pa-
tient is referred to a specialist in secondary care 
settings, referral letters containing patient’s notes 
and laboratory results are sent back to primary care 
doctors, for inclusion into the patient’s medical 
records. As such, personal information, lifestyle, 
and medical history on relevant morbidities could be 
extracted from the participants’ records. We extracted 
total cholesterol levels and systolic blood pressure for 
two years before to six months after the index date. If 
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participants had a record of being a smoker within five 
years before the index date or any time after the index 
date we defined them as a smoker, otherwise a non-
smoker. Statin use was coded as yes if participants had 
a record of a statin prescription in the two years before 
and within six months after the index date. History of 
type 2 diabetes and hypertension were defined as a 
record occurring any time before or at the index date.
Data analysis
Analyses were performed using a two step approach 
for data synthesis. Firstly, we analysed each of the 
four databases separately and then we used a random 
effect meta-analysis to pool the estimates for each 
of these studies. Matched pairs (participants with 
NAFLD matched with participants without NAFLD) 
are described using percentages for categorical 
variables, means and standard deviations for normally 
distributed variables, and medians and interquartile 
ranges for skewed variables. Within each group 
we estimated incidence rates of AMI and stroke by 
dividing the number of incident events by the total 
number of person years at risk, and the corresponding 
95% confidence intervals were estimated assuming a 
Poisson distribution. Hazard ratios for incident AMI 
or stroke associated with a diagnosis of NAFLD were 
estimated using Cox proportional hazards models for 
each study independently. The models were stratified 
by matching variables and progressively adjusted 
in multivariable models for age and smoking status, 
and age, smoking status, type 2 diabetes, statin use, 
hypertension, systolic blood pressure, and total 
cholesterol level (in subsets of participants with data 
available). We then pooled hazard ratios across studies 
by random effects meta-analysis. The Q statistic was 
used to test heterogeneity across databases,20 which 
has a χ2 distribution with 2 degrees of freedom on 
the null hypothesis of no heterogeneity, and the 
corresponding P value was obtained. We also reported 
the I2 statistic, which gives the percentage of variation 
among studies due to heterogeneity across databases, 
rather than to variation among individual people 
within a database.21 Hazard ratios were estimated by 
prespecified subgroups according to sex, BMI (obese, 
≥30 v normal weight), smoking status, age group (<55 
years v ≥55 years old), hypertension status, and type 2 
diabetes status. For this, we added an interaction term 
to the models between NAFLD diagnosis and subgroup, 
and we then used random effects meta-analyses to pool 
hazard ratios for each subgroup across databases. We 
excluded values that were physiologically implausible: 
BMI less than 15, laboratory values greater than the 
mean in the database plus three times the standard 
deviation, aspartate aminotransferase and alanine 
aminotransferase levels less than 5 iU/L, and platelet 
counts less than 5×109/L. Missing data were not 
imputed and analyses were run in the samples of 
participants with no missing data for all variables in 
the models.
The data were locally extracted within each centre 
after quality control checks using a standardised script. 
They were then centrally analysed using Stata v14 on 
the secure remote research server of the EMIF Platform.
Patient and public involvement
No patients were involved in setting the research 
question or the outcome measures. However, patients 
were involved in the setup of the overall European 
Medical Information Framework consortium, which 
underpinned this work. No patients were asked to 
advise on interpretation or writing up of results. The 
results of the research will be disseminated to patients 
through the European Medical Information Framework 
website (emif.eu).
results
Primary care records for 21 952 040 patients resident 
in four European countries were accessed: Italy (HSD, 
n=1 542 672), Netherlands (IPCI, n=2 225 925), Cata-
lonia, Spain (SIDIAP, n=5 488 397), and UK (THIN, 
n=12 695 046).13-16 After excluding patients with 
a history of alcohol misuse, a past AMI or stroke 
event, less than one year of enrolment, and less than 
six months of follow-up before and after the index 
date, 120 795 participants with an incident NAFLD 
diagnosis (21 627 in HSD, 12 595 in IPCI, 67 109 in 
SIDIAP, and 19 464 in THIN) were included.
baseline characteristics
The duration of follow-up before and after the index 
date, age distribution, and percentage of men were 
comparable in the NAFLD and non-NAFLD groups in 
each of the four databases (table 1).13-16 Average follow-
up after the index date was lowest in IPCI (median 2.1 
years (interquartile range 1.2-3.4 years) and highest in 
HSD (5.5 (3.0-8.1) years) in participants with NAFLD. 
Traditional cardiovascular risk factors were more 
common in participants with NAFLD compared with 
matched controls: proportions of current smokers 
(except for THIN), participants with a history of type 
2 diabetes or hypertension, BMI levels, and systolic 
blood pressure levels were higher in participants with 
NAFLD compared with matched controls in each of the 
four databases.
Outcome incidence rates
The total number of person years’ follow-up for 
participants with NAFLD or NASH ranged from 85 361 
in THIN to 259 008 in SIDIAP (supplementary table 
2). Unadjusted incidence rates of AMI and stroke were 
higher in participants with NAFLD compared with 
matched controls and differed across databases: rates 
of AMI were highest in IPCI (4.36 (95% confidence 
interval 3.66 to 5.15) and 3.17 (3.11 to 3.24) per 1000 
person years in participants with and without NAFLD, 
respectively); whereas rates of stroke were highest 
in HSD (7.88 (7.39 to 8.39) and 6.27 (6.22 to 6.32) 
per 1000 person years, respectively) (supplementary 
table 2). In participants with NAFLD, the number of 
incident AMI events ranged from 137 (in IPCI) to 414 
(in SIDIAP), and stroke events from 156 (in IPCI) to 
962 (in HSD).
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To investigate whether these associations were 
modified by common risk factors for cardiovascular 
disease, we defined subsets of participants in whom we 
had data on total cholesterol level and systolic blood 
pressure, and participants for whom we additionally 
held data on BMI and HDL cholesterol level. In the 
former subset, 86 098 participants with NAFLD 
experienced 747 AMI events and 1666 stroke events 
during follow-up (supplementary table 3). Participants 
in the subset with more complete data were more likely 
to have type 2 diabetes, hypertension, be prescribed 
statins, and be current smokers compared with the 
entire NAFLD cohort in each database (supplementary 
table 4).
Hazard ratios for incident aMi
When adjustments were made for age, sex, and smoking, 
the hazard ratio for incident AMI in participants with 
NAFLD ranged from 1.03 (95% confidence interval 
0.90 to 1.18) in HSD to 1.31 (1.16 to 1.49) in THIN; the 
pooled hazard ratio was 1.17 (1.05 to 1.30), I2=66%, 
P=0.03 for heterogeneity) (fig 1). When analyses were 
done in the subset of participants with full data on 
traditional risk factors for cardiovascular disease, 
the age, sex, and smoking adjusted hazard ratio for 
incident AMI was 1.08 (0.96 to 1.23) which, when 
adjusted for systolic blood pressure, type 2 diabetes, 
total cholesterol level, statin use, and hypertension 
attenuated to 1.01 (0.91 to 1.12), I2=48.4%, P=0.12 
for heterogeneity). Excluding participants with NASH 
did not alter the lack of association between NAFLD 
and AMI (supplementary fig 1). In subgroup analyses, 
pooled hazard ratios did not significantly differ 
according to presence or absence of type 2 diabetes or 
hypertension, or by smoking status, age group, obesity, 
and sex (although estimates were slightly higher in 
women than in men) (supplementary fig 2).
Hazard ratios for incident stroke
For the model minimally adjusted for age, sex, and 
smoking the pooled hazard ratio for incident stroke 
was 1.18 (1.11 to 1.24) with low levels of heterogeneity 
across databases (I2=29.3% and P=0.24) (fig 2). In 
the subset with mostly complete data on risk factors, 
the pooled hazard ratio for stroke was 1.10 (1.04 to 
1.15) in the minimally adjusted model, which became 
attenuated to 1.04 (0.99 to 1.09), I2=0.0%, P=0.92 for 
heterogeneity) after adjustment for type 2 diabetes, 
systolic blood pressure, total cholesterol level, statin 
use, and hypertension. Associations between NAFLD 
and incident stroke were unchanged after excluding 
participants with NASH (supplementary fig 3). 
Subgroup analyses did not identify any significant 
differences, although the hazard ratio was marginally 
higher for woman than for men (1.15 v 1.04) 
(supplementary fig 4).
Hazard ratios were not materially different in 
sensitivity analyses including recurrent AMI and stroke 
events and participants with less than six months of 
follow-up (supplementary figs 5-7).
discussion
In this real world primary care record study of 205 046 
cardiovascular events in 120 795 adults and 9 647 644 
table 1 | Descriptive characteristics of participants with non-alcoholic fatty liver disease (naFlD) and matched participants in four european primary 
care databases
characteristics
HsD (italy) iPci (netherlands) siDiaP (spain) tHin (uK)
naFlD
Matched  
non- naFlD naFlD
Matched  
non- naFlD naFlD
Matched  
non- naFlD naFlD
Matched  
non- naFlD
Median (interquartile range) 
follow-up before index date 
(years)
7.5 (4.7-10.4) 7.6 (4.8-10.4) 2.5 (1.4-3.9) 2.5 (1.4-3.9) 5.1 (3.1-6.8) 5.1 (3.1-6.8) 13.4 (5.8-22.9) 14.3 (6.6-23.2)
Median (interquartile range) 
follow-up post index date 
(years)
5.5 (3.0-8.1) 5.4 (3.0-8.1) 2.1 (1.2-3.4) 2.2 (1.2-3.4) 3.7 (2.0-5.6) 3.7 (2.0-5.7) 3.5 (1.8-6.1) 3.5 (1.8-6.1)
Mean (SD) age (years) 55.6 (14.2) 54.6 (13.5) 56.1 (13.6) 55.6 (13.3) 55.6 (13.3) 54.2 (12.9) 53.3 (13.1) 52.9 (13.2)
Men (%) 57.2 54.9 48.6 48.1 52.5 48.8 51.1 50.4
Current smokers (%) 11.3 9.1 17.2 11.1 17.8 15.4 17.3 18.7
Mean (SD) body mass index 29.7 (5.0) 27.5 (5.0) 31.0 (5.4) 28.3 (5.2) 31.4 (5.1) 28.7 (5.1) 32.4 (5.9) 28.5 (5.9)
History of type 2  
diabetes (%)
17.0 10.7 19.8 8.6 19.4 9.9 20.1 6.5
History of hypertension (%) 46.2 35.7 34.6 25.0 42.0 28.3 40.0 24.8
Median (interquartile range) 
aspartate transaminase 
(IU/L)
24 (19-33) 20.7 (17-25) 29 (22-40) 23 (20-28) 29 (22-40) 21 (18-27) 32 (24-47) 22 (19-27)
Median (interquartile range) 
alanine transaminase (IU/L)
30 (20-49) 21 (16-30) 37 (25-56) 25 (18-33) 35 (23-54) 20 (15-28) 46 (29-69) 23 (17-31)
Mean (SD) total cholesterol 
(mmol/L)
5.41 (1.06) 5.43 (1.03) 5.31 (1.16) 5.35 (1.10) 5.40 (1.01) 5.37 (0.97) 5.23 (1.24) 5.16 (1.16)
Mean (SD) HDL cholesterol 
(mmol/L)
1.31 (0.34) 1.43 (0.38) 1.21 (0.31) 1.36 (0.36) 1.27 (0.32) 1.42 (0.37) 1.25 (0.36) 1.43 (0.77)
Mean (SD) systolic blood 
pressure (mm Hg)
132.8 (15.2) 131.7 (15.7 138.2 (17.5) 136.7 (17.7) 131.7 (13.6) 129.2 (14.2) 134.3 (14.8) 131.9 (15.8)
HDL=high density lipoprotein.
*After imputation of missing as non-smokers. For laboratory values, outlier values greater than mean+3×standard deviation were excluded (mean and standard deviation computed separately in 
participants with and without NAFLD separately).
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matched controls we found that a recorded diagnosis 
of non-alcoholic fatty liver disease (NAFLD) or non-
alcoholic steatohepatitis (NASH) is more weakly 
associated with any excess risk of acute myocardial 
infarction (AMI) and stroke beyond known associated 
risk factors. In the current study, the age and sex 
adjusted hazard ratio was around 1.2 rather than 1.6 to 
2.0-fold reported in recent meta-analyses of previous 
cohorts.9 10 When we adjusted for other covariates in 
the subset of participants with more complete data on 
risk factors, the hazard ratio moved towards the null 
for both AMI and stroke with sequential adjustment for 
these risk factors. These data suggest that a diagnosis 
of NAFLD in routine clinical practice across Europe 
does not necessarily indicate the need for AMI or stroke 
preventive treatments. Rather, our results suggest that 
the risk of cardiovascular disease should be assessed 
in these people in the standard way using risk scores, 
with no strong case yet to consider NAFLD as a risk 
enhancer. This means that for people with NAFLD 
to be identified at high risk, the coexistence of other 
well known risk factors (eg, diabetes or hypertension, 
dyslipidaemia) is required, which a reasonable pro-
portion will have, and such risk factors should be dealt 
with as for usual guideline recommendations. This is 
analogous to the situation for prediabetes where the 
risk of cardiovascular disease should be based on 
usual risk scores without a risk multiplier.22
strengths of this study
Owing to the large scale of the databases used in our 
study, we were able to match each participant with 
Total population
  Adjusted for age and smoking status
    HSD
    IPCI
    SIDIAP
    THIN
    Subtotal: P-het=0.032; I2=66.0%
Subset*
  Adjusted for age and smoking status
    HSD
    IPCI
    SIDIAP
    THIN
    Subtotal: P-het=0.047; I2=62.2%
  Further adjusted for diabetes, systolic
  blood pressure, and total cholesterol
    HSD 
    IPCI
    SIDIAP
    THIN
    Subtotal: P-het=0.049; I2=61.9%
  Further adjusted for statin use and hypertension
    HSD
    IPCI
    SIDIAP
    THIN
    Subtotal: P-het=0.121; I2=48.4%
1.03 (0.90 to 1.18)
1.27 (1.07 to 1.50)
1.11 (1.01 to 1.22)
1.31 (1.16 to 1.49)
1.17 (1.05 to 1.30)
0.88 (0.74 to 1.05)
1.25 (1.02 to 1.55)
1.09 (0.97 to 1.21)
1.16 (1.01 to 1.34)
1.08 (0.96 to 1.23)
  
0.88 (0.74 to 1.05)
1.25 (1.01 to 1.54)
1.07 (0.96 to 1.19)
1.15 (1.00 to 1.33)
1.07 (0.95 to 1.22)
0.86 (0.72 to 1.03)
1.18 (0.95 to 1.45)
0.99 (0.89 to 1.10)
1.07 (0.92 to 1.23)
1.01 (0.91 to 1.12)
0.8 1.2 1.41 1.6
Database Hazard ratio
(95% CI)
Hazard ratio
(95% CI)
15 014/221
9625/137
23 238/414
19 946/263
67 823/1035
7329/126
4704/90
14 933/334
10 496/197
37 462/747
7329/126
4704/90
14 933/334
10 496/197
37 462/747
  
7329/126
4704/90
14 933/334
10 496/197
37 462/747
Events in non-
NAFLD/NAFLD
Fig 1 | Hazard ratios (95% confidence intervals) for acute myocardial infarction in participants with non-alcoholic fatty 
liver disease (naFlD). Data for age, sex, and smoking status were available for 120 795 participants with naFlD and 
9 647 644 matched participants without naFlD. *subset analyses were restricted to participants with data for age, 
smoking status, type 2 diabetes, systolic blood pressure, total cholesterol level, statin use, and hypertension (86 098 
participants with naFlD and 4 664 988 matched controls, respectively). analyses were progressively adjusted for 
age, smoking status, type 2 diabetes, systolic blood pressure, total cholesterol level, statin use, and hypertension. 
Weights are from random effect meta-analysis and are inversely proportional to the variance of the estimated hazard 
ratios (therefore proportional to the number of events contributing the hazard ratios). statin use in the Health 
improvement network (tHin, united Kingdom) was missing and therefore imputed. HsD=Health search Database 
(italy); iPci=integrated Primary care information (netherlands); siDiaP=information system for research in Primary 
care (spain); P-het=P value for heterogeneity
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a recorded diagnosis of NAFLD with several people 
without such a diagnosis, from the same general 
practice, sex, and age within five years either way as 
the participants with NAFLD. We conducted our study 
concurrently in four European databases holding 
primary care data that have been extensively used for 
research, each one with multiple publications, and all 
part of the EU-Adverse Drug Reactions (ADR) Alliance, 
which conducts voluntary or mandated European 
Union-wide post-authorisation safety studies.13-16 18 
Furthermore, other important diagnoses have been 
validated in these databases, for example AMI,23 
strengthening our hypothesis that these electronic 
health records capture recording of clinical diagnoses 
in primary care.
comparison with previous studies
Our routine care data showed differential, weaker, 
associations of NAFLD with an excess of incident 
AMI or stroke outcomes over and above associated 
risk factors compared with meta-analyses of AMI or 
stroke event data in previous observation cohorts.9 10 
One potential is that, unlike previous observation 
cohorts, we comprehensively adjusted for known risk 
factors for cardiovascular disease when available. We 
also adjusted using continuous rather than categorical 
measures, and we considered current lipid lowering 
treatments. Participants without NAFLD were matched 
according to the general practice, which limited 
confounding by social class, something cohort studies 
have also rarely considered. Social class is an often 
Total population
  Adjusted for age and smoking status
    HSD
    IPCI
    SIDIAP
    THIN
    Subtotal: P-het=0.236; I2=29.3%
Subset*
  Adjusted for age and smoking status
    HSD
    IPCI
    SIDIAP
    THIN
    Subtotal: P-het=0.606; I2=0%
  Further adjusted for diabetes, systolic
  blood pressure, and total cholesterol
    HSD 
    IPCI
    SIDIAP
    THIN
    Subtotal: P-het=0.671; I2=0%
  Further adjusted for statin use and hypertension
    HSD
    IPCI
    SIDIAP
    THIN
    Subtotal: P-het=0.922; I2=0%
1.16 (1.09 to 1.23)
1.15 (0.99 to 1.35)
1.14 (1.07 to 1.22)
1.34 (1.17 to 1.53)
1.18 (1.11 to 1.24)
1.06 (0.98 to 1.14)
1.10 (0.90 to 1.35)
1.13 (1.05 to 1.22)
1.13 (0.96 to 1.34)
1.10 (1.04 to 1.15)
 
1.05 (0.98 to 1.13)
1.09 (0.90 to 1.34)
1.12 (1.04 to 1.21)
1.12 (0.95 to 1.32)
1.09 (1.04 to 1.14)
 
1.02 (0.94 to 1.10)
1.06 (0.87 to 1.29)
1.05 (0.97 to 1.13)
1.05 (0.89 to 1.25)
1.04 (0.99 to 1.09)
0.8 1.2 1.41 1.6
Database Hazard ratio
(95% CI)
Hazard ratio
(95% CI)
60 082/962
11 902/156
45 658/854
16 359/215
134 001/2187
37 606/719
6059/101
31 561/702
8656/144
83 882/1666
  
37 606/719
6059/101
31 561/702
8656/144
83 882/1666
37 606/719
6059/101
31 561/702
8656/144
83 882/1666
Events in non-
NAFLD/NAFLD
Fig 2 | Hazard ratios (95% confidence intervals) for stroke in participants with non-alcoholic fatty liver disease 
(naFlD). Data for age, sex, and smoking status were available for 120 795 participants with naFlD and 9 647 644 
matched participants without naFlD. *subset analyses were restricted to participants with data for age, smoking 
status, type 2 diabetes, systolic blood pressure, total cholesterol level, statin use, and hypertension (86 098 naFlD 
and 4 664 988 matched controls, respectively). analyses were progressively adjusted for age, smoking status, 
type 2 diabetes, systolic blood pressure, total cholesterol level, statin use, and hypertension. Weights are from 
random effect meta-analysis and are inversely proportional to the variance of the estimated hazard ratios (therefore 
proportional to the number of events contributing the hazard ratios). statin use in the Health improvement network 
(tHin, united Kingdom) was missing and therefore imputed. HsD=Health search Database (italy); iPci=integrated 
Primary care information (netherlands); siDiaP=information system for research in Primary care (spain); P-het=P 
value for heterogeneity
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overlooked but increasingly important confounder 
as there are clear gradients in obesity and diabetes 
risks by social class,24 factors that predict differences 
in NAFLD occurrence, suggesting NAFLD is also 
strongly socially patterned. Social class is also a strong 
predictor of AMI or stroke events and is now included 
in several validated risk scores.25 26 Cardiovascular 
and NAFLD risk vary by ethnicity, but we were unable 
to assess this in the current study because these data 
are not held in the Health Search Database (HSD), 
Information System for Research in Primary Care 
(SIDIAP), and Integrated Primary Care Information 
(IPCI).27 Although multivariable adjustment took into 
account confounding for several potential factors 
(smoking, medical history, obesity), and despite our 
extensive matching, residual confounding could still 
be present owing to other factors (such as body mass 
index (BMI) and high density lipoprotein cholesterol 
level), which we have not included here, but these 
omissions would increase rather than nullify hazards. 
We do, however, recognise that the need to have more 
complete risk factor data in some of our analyses could 
have marginally attenuated risk differences between 
those with and without NAFLD.
alcohol as confounder
To eliminate confounding from liver disease poten-
tially driven by alcohol, we excluded adults with 
other chronic liver conditions such as alcoholic liver 
disease and those with a coded diagnosis of alcohol 
misuse. Alcohol consumption is difficult to determine 
accurately in clinical practice and is therefore 
unreliably recorded in routine care records. A recent 
major alcohol study combining 83 prospective cohorts 
in which alcohol consumption was carefully evaluated 
and recorded, did not show an overall lower risk for 
total cardiovascular disease with alcohol.28 Non-fatal 
AMI risk was slightly lower (hazard ratio 0.94 for 100 g 
higher alcohol intake weekly), and the risk of all other 
adverse vascular outcomes including stroke (1.14 for 
100 g higher alcohol intake weekly) was higher. Hence, 
if the participants with NAFLD or NASH in the current 
study consumed moderate amounts of alcohol more 
often than their matched counterparts, our results 
for AMI might have been biased towards the null, but 
stroke risk should have been biased the other way. That 
the hazard ratios associated with alcohol are modest 
and that results for our two main outcomes of AMI 
and stroke show broadly consistent results, however, 
suggest any confounding is likely to be minimal.
We recently used these databases to show that the 
recorded age and sex specific point prevalence of 
NAFLD between 2007 and 2014 is much lower than 
expected, with less than 2% of the total number of 
patients registered in the databases having a recorded 
diagnosis of NAFLD.17 It is therefore possible that we 
did not identify a representative sample of adults with 
NAFLD. Even if cohort studies have overestimated 
the prevalence of NAFLD in the general population, 
many participants might have NAFLD but without a 
diagnosis made or recorded, and they were included 
in our population of matched participants. The 
characteristics of the participants with NAFLD iden-
tified in our study are, however, consistent with 
published cohort studies. In a recent meta-analysis 
of 86 cohort studies in 22 countries, metabolic 
comorbidities associated with NAFLD included 
obesity (51.3%, 95% confidence interval 41.4% to 
61.2%), type 2 diabetes (22.5%, 17.9% to 27.9%), 
and hypertension (39.3%, 33.2% to 45.9%).29 In our 
summary data (table 1), average BMI was greater than 
30 in three of the electronic health records for NAFLD, 
average diabetes percentages were around 19%, and 
the average proportion with hypertension was around 
40%, results near identical to the meta-analysis,29 
lending strong external validity to our cohort make-up. 
We therefore believe that those with coded NAFLD or 
NASH have been correctly identified as they have all the 
associated clinical characteristics of the condition and 
at levels near identical to those proved to have NAFLD 
using imaging techniques. We accept a proportion 
in the matched population will have undiagnosed 
NAFLD but these will be diluted out by others without 
NAFLD: evidenced by the average characteristics of 
the matched controls. We also could not determine 
how doctors diagnosed NAFLD in each case, but these 
data suggest that those identified did have NAFLD.17 
From a practical point of view, it is not possible to 
apply a cardiovascular risk multiplier (if appropriate) 
to a particular condition in people without a diagnosis 
of that condition. Therefore, despite the low point 
prevalence, our data represent the pattern of AMI 
and stroke risk in people with a recorded diagnosis of 
NAFLD or NASH.
additional strengths and limitations of this study
To limit heterogeneity across studies, we harmonised 
code lists for clinical events and ensured that codes 
in multiple terminologies all mapped to the same 
unified medical language system concepts. After local 
data extraction, one analyst formatted and analysed 
data in the same way for the four databases13-16 
on the European Medical Information Framework 
remote server. However, we still observed statistically 
significant heterogeneity across studies, which was 
only partially accounted for by progressive adjustment. 
This is probably due to major differences in healthcare 
systems between the four countries (eg, NAFLD is 
diagnosed at a more advanced stage in The Health 
Improvement Network (THIN)) as well as terminology 
used to record NAFLD and outcomes. Variation in 
the methods used to diagnose NAFLD and NASH30 31 
and the extent to which coding was completed also 
contributes to heterogeneity. We recognise that the 
difference between HSD and the other cohorts was 
a main contributor to the observed heterogeneity.” 
The HSD findings seemed to be robust on a recheck. 
Sensitivity analyses on incident AMI including only the 
other three more congruent cohorts, however, showed 
similarly low hazards for AMI in participants with 
NAFLD. Hence conclusions remain the same whether 
or not data were included from HSD.
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conclusion
Associations of an existing and recorded diagnosis of 
NAFLD in routine electronic health records with both 
incident AMI and stroke were modest (hazard ratios 
around 1.2) in age, sex, and smoking adjusted models. 
Moreover, in the cohort where we had more complete 
data on cardiovascular risk factors, hazard ratios for 
AMI and stroke were attenuated with adjustment for 
known cardiovascular risk factors and were null in 
adjusted models. Thus, NAFLD was not meaningfully 
associated with the outcomes investigated in our study. 
A diagnosis of NAFLD does warrant risk assessment for 
the stage of liver disease, and behaviour and lifestyle 
advice not only for reduction of liver fat but also for 
benefits of weight loss on AMI and stroke risk factors, 
including lipids, systolic blood pressure, and the 
development of diabetes. Among the large numbers 
of patients with NAFLD, some, if not many, could be 
at increased risk of AMI and stroke outcomes. Further 
study is, however, needed to identify such people and 
quantify that risk.
For the time being, it should not be assumed that 
people with a diagnosis of NAFLD are automatically at 
increased risk of AMI or stroke. Rather, it is important 
to do a cardiovascular risk assessment in people with 
a diagnosis of NAFLD, in addition to checking for 
undiagnosed diabetes. Presently, such cardiovascular 
risk assessment should be carried out in the same way 
as for the general population.
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